Daiichi Sankyo

Japan to buy 1.4 mln doses of Daiichi Sankyo COVID vaccine
Japan to buy 1.4 mln doses of Daiichi Sankyo COVID vaccine
Reuters
Japan
Daiichi Sankyo
COVID-19
vaccines
Flag link:
Daiichi-Sankyo ups revenue forecast thanks to massive Merck deal
Daiichi-Sankyo ups revenue forecast thanks to massive Merck deal
Fierce Biotech
Daiichi Sankyo
Merck
antibody-drug conjugate
Flag link:
‘We knew it was there’: AbbVie CEO says company favored internal work over potential Daiichi deal
‘We knew it was there’: AbbVie CEO says company favored internal work over potential Daiichi deal
Fierce Biotech
AbbVie
Daiichi Sankyo
Merck
antibody-drug conjugate
Flag link:
ESMO: AstraZeneca-Daiichi get clarity on patient deaths for Enhertu follow up Dato-DXd, survival data still unclear
ESMO: AstraZeneca-Daiichi get clarity on patient deaths for Enhertu follow up Dato-DXd, survival data still unclear
Fierce Biotech
ESMO
Daiichi Sankyo
AstraZeneca
Enhertu
patient deaths
clinical trials
non-small cell lung cancer
Flag link:
Merck pays $4B upfront for rights to 3 Daiichi ADCs in huge bet on post-Keytruda future
Merck pays $4B upfront for rights to 3 Daiichi ADCs in huge bet on post-Keytruda future
Fierce Biotech
Merck
Daiichi Sankyo
AstraZeneca
antibody-drug conjugate
Flag link:
Seagen wins future royalties in Enhertu patent dispute
Seagen wins future royalties in Enhertu patent dispute
Pharmaphorum
Seagen
Daiichi Sankyo
breast cancer
Enhertu
drug royalties
Flag link:
BioNTech takes another leaf out of Daiichi playbook, paying $70M for HER3-directed ADC
BioNTech takes another leaf out of Daiichi playbook, paying $70M for HER3-directed ADC
Fierce Biotech
BioNTech
Daiichi Sankyo
antibody-drug conjugate
breast cancer
Flag link:
Daiichi Sankyo reports positive results from trial of breast cancer therapy
Daiichi Sankyo reports positive results from trial of breast cancer therapy
Clinical Trials Arena
Daiichi Sankyo
clinical trials
Dato-DXd
breast cancer
Flag link:
AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead
AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead
BioSpace
AstraZeneca
Daiichi Sankyo
breast cancer
antibody-drug conjugate
clinical trials
Flag link:
AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind
AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind
Fierce Biotech
AstraZeneca
Daiichi Sankyo
antibody-drug conjugate
non-small cell lung cancer
Dato-DXd
Flag link:
The 10 highest value R&D projects in biopharma
The 10 highest value R&D projects in biopharma
Fierce Biotech
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
Flag link:
Daiichi Sankyo to close Japanese research and development subsidiary
Daiichi Sankyo to close Japanese research and development subsidiary
Pharmaceutical Business Review
Daiichi Sankyo
Japan
R&D
RD Novare
Flag link:
Daiichi Sankyo will remain 'dominant' in ADC market for oncology treatments
Daiichi Sankyo will remain 'dominant' in ADC market for oncology treatments
Biopharma Reporter
Daiichi Sankyo
antibody drug conjugate
oncology
Seagen
Roche
Flag link:
Enhertu offers survival benefits in Phase II solid tumour trial
Enhertu offers survival benefits in Phase II solid tumour trial
Clinical Trials Arena
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
solid tumors
Flag link:
FDA okays Daiichi Sankyo’s Vanflyta for first-line AML
FDA okays Daiichi Sankyo’s Vanflyta for first-line AML
Pharmaphorum
Daiichi Sankyo
Vanflyta
FDA
AML
Flag link:
AstraZeneca stock slides as pivotal lung cancer readout on Daiichi-partnered ADC spooks investors
AstraZeneca stock slides as pivotal lung cancer readout on Daiichi-partnered ADC spooks investors
Fierce Biotech
AstraZeneca
Daiichi Sankyo
antibody-drug conjugate
Enhertu
clinical trials
non-small cell lung cancer
Flag link:
ASCO 2023 – early first-line lung cancer data mined for datopotamab gold
ASCO 2023 – early first-line lung cancer data mined for datopotamab gold
EP Vantage
ASCO 2023
Daiichi Sankyo
AstraZeneca
datopotamab deruxtecan
non-small cell lung cancer
Flag link:
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
BioPharma Dive
ASCO 2023
antibody-drug conjugate
Merck
BioNTech
Daiichi Sankyo
Flag link:
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:

Pages